For Device VCs, the Eyes, Heart and Stomach Have It

Anyone with access to the right data can tell you which technologies and medical specialties are commanding the highest valuations from device VCs. But what would it be worth to know which companies will be commanding the top prices in the next year? A survey of more than a dozen VCs--who participated with a promise of anonymity--with money to invest draws a very clear picture about what investment opportunities they might find worth fighting over and the areas they'll ignore.

Anyone with access to the right data can tell you which technologies and medical specialties are commanding the highest valuations from venture capital investors. But what would it be worth to know which companies will be commanding the top prices in the next year? A survey of more than a dozen VCs—who participated with a promise of anonymity—with money to invest draws a very clear picture about what investment opportunities they might find worth fighting over and the areas they'll ignore.

Among areas they favor are ophthalmology, atrial fibrillation, endogastric devices, neurostimulation, heart valves, and molecular diagnostics. In some cases, like atrial fibrillation and heart valves, venture investors were impressed both by the potential market and the actual returns realized from high-profile acquisitions in each space. Last year, Medtronic PLC acquired atrial fibrillation company Ablation Frontiers Inc. (now Medtronic Ablation Frontiers LLC) for $225 million plus earn-outs. [See Deal] That came just a few weeks before Medtronic announced its $700 million acquisition of aortic valve maker CoreValve Inc. (now Medtronic CoreValve LLC)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 
• By 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, content format or the method in which you receive and access Medtech Insight, or if you love it how it is, now is the time to have your voice heard.

Patients With Movement Disorders Will Benefit From Medtronic’s Expanded MRI Labeling For DBS

 
• By 

Medtronic announced it received expanded MRI labeling for its DBS systems, which is critical, given that almost 70% of all DBS-eligible patients will likely need an MRI at some point in their care, says Ashwini Sharan, CMO for Medtronic Neuromodulation.

Podcast: Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic

 

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement andcompliance with the US FDA Lab Developed Test ruling.

More from Medtech Insight

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

MORE Details On MHRA’s Online Platform For Post Market Surveillance

 
• By 

Post-market surveillance regulations for medtech system users in Great Britain coming into force on 16 June will make new data requirements under new compliance deadlines.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.